全文获取类型
收费全文 | 55354篇 |
免费 | 4150篇 |
国内免费 | 167篇 |
专业分类
耳鼻咽喉 | 643篇 |
儿科学 | 1470篇 |
妇产科学 | 1067篇 |
基础医学 | 6841篇 |
口腔科学 | 1092篇 |
临床医学 | 5692篇 |
内科学 | 12045篇 |
皮肤病学 | 765篇 |
神经病学 | 5147篇 |
特种医学 | 1694篇 |
外国民族医学 | 1篇 |
外科学 | 7537篇 |
综合类 | 1022篇 |
一般理论 | 41篇 |
预防医学 | 5009篇 |
眼科学 | 1252篇 |
药学 | 4133篇 |
1篇 | |
中国医学 | 76篇 |
肿瘤学 | 4143篇 |
出版年
2023年 | 243篇 |
2022年 | 378篇 |
2021年 | 880篇 |
2020年 | 563篇 |
2019年 | 871篇 |
2018年 | 1068篇 |
2017年 | 797篇 |
2016年 | 890篇 |
2015年 | 974篇 |
2014年 | 1456篇 |
2013年 | 2178篇 |
2012年 | 3282篇 |
2011年 | 3319篇 |
2010年 | 1854篇 |
2009年 | 1679篇 |
2008年 | 3153篇 |
2007年 | 3452篇 |
2006年 | 3432篇 |
2005年 | 3345篇 |
2004年 | 3274篇 |
2003年 | 3123篇 |
2002年 | 3077篇 |
2001年 | 882篇 |
2000年 | 765篇 |
1999年 | 837篇 |
1998年 | 750篇 |
1997年 | 580篇 |
1996年 | 587篇 |
1995年 | 552篇 |
1994年 | 500篇 |
1993年 | 454篇 |
1992年 | 607篇 |
1991年 | 552篇 |
1990年 | 577篇 |
1989年 | 524篇 |
1988年 | 517篇 |
1987年 | 521篇 |
1986年 | 482篇 |
1985年 | 469篇 |
1984年 | 510篇 |
1983年 | 437篇 |
1982年 | 471篇 |
1981年 | 404篇 |
1980年 | 366篇 |
1979年 | 349篇 |
1978年 | 319篇 |
1977年 | 287篇 |
1976年 | 267篇 |
1975年 | 252篇 |
1974年 | 260篇 |
排序方式: 共有10000条查询结果,搜索用时 0 毫秒
1.
This article describes a case of anaphylaxis secondary to chlorhexidine during urethral catheterisation. Despite little evidence for the use of antiseptic lubricants in preventing catheter-associated urinary tract infections, the distribution and use of such products continues to be widespread. Chlorhexidine-free lubricating gel is widely available and should be used for urological procedures wherever possible. 相似文献
2.
3.
Edward J. Holland Walter O. Whitley Kenneth Sall Stephen S. Lane Aparna Raychaudhuri Steven Y. Zhang 《Current medical research and opinion》2016,32(10):1759-1765
Objective: Report efficacy findings from three clinical trials (one phase 2 and two phase 3 [OPUS-1, OPUS-2]) of lifitegrast ophthalmic solution 5.0% for treatment of dry eye disease (DED).Research design and methods: Three 84-day, randomized, double-masked, placebo-controlled trials. Adults (≥18 years) with DED were randomized (1:1) to lifitegrast 5.0% or matching placebo. Changes from baseline to day 84 in signs and symptoms of DED were analyzed.Main outcome measures: Phase 2, pre-specified endpoint: inferior corneal staining score (ICSS; 0–4); OPUS-1, coprimary endpoints: ICSS and visual-related function subscale (0–4 scale); OPUS-2, coprimary endpoints: ICSS and eye dryness score (EDS, VAS; 0–100).Results: Fifty-eight participants were randomized to lifitegrast 5.0% and 58 to placebo in the phase 2 trial; 293 to lifitegrast and 295 to placebo in OPUS-1; 358 to lifitegrast and 360 to placebo in OPUS-2. In participants with mild-to-moderate baseline DED symptomatology, lifitegrast improved ICSS versus placebo in the phase 2 study (treatment effect, 0.35; 95% CI, 0.05–0.65; p?=?0.0209) and OPUS-1 (effect, 0.24; 95% CI, 0.10–0.38; p?=?0.0007). Among more symptomatic participants (baseline EDS ≥40, recent artificial tear use), lifitegrast improved EDS versus placebo in a post hoc analysis of OPUS-1 (effect, 13.34; 95% CI, 2.35–24.33; nominal p?=?0.0178) and in OPUS-2 (effect, 12.61; 95% CI, 8.51–16.70; p?<?0.0001).Limitations: Trials were conducted over 12 weeks; efficacy beyond this period was not assessed.Conclusions: Across three trials, lifitegrast improved ICSS in participants with mild-to-moderate baseline symptomatology in two studies, and EDS in participants with moderate-to-severe baseline symptomatology in two studies. Based on the overall findings from these trials, lifitegrast shows promise as a new treatment option for signs and symptoms of DED. 相似文献
4.
5.
6.
Suchi Raghunathan Corey L. Reynolds Robert J. Schwartz M. David Stewart Bradley K. McConnell 《Fundamental & clinical pharmacology》2019,33(1):25-30
Inbred mouse strains are the most widely used mammalian model organism in biomedical research owing to ease of genetic manipulation and short lifespan; however, each inbred strain possesses a unique repertoire of deleterious homozygous alleles that can make a specific strain more susceptible to a particular disease. In the current study, we report dystrophic cardiac calcinosis (DCC) in C.B‐17 SCID male mice at 10 weeks of age with no significant change in cardiac function. Acquisition of DCC was characterized by myocardial injury, fibrosis, calcification, and necrosis of the tissue. At 10 weeks of age, 38% of the C.B‐17 SCID mice from two different commercial colonies exhibited significant calcinosis on the ventricular epicardium, predominantly on the right ventricle. The frequency of calcinosis was more than 50% for mice obtained from Taconic's Cambridge City colony and 25% for mice obtained from Taconic's German Town colony. Interestingly, the DCC phenotype did not affect cardiac function at 10 weeks of age. No differences in echocardiography or electrocardiography were observed between the calcinotic and non‐calcinotic mice from either colony. Our findings suggest that C.B‐17 SCID mice exhibit DCC as early as 10 weeks of age with no significant impact on cardiac function. This strain of mice should be cautiously considered for the study of cardiac physiology. 相似文献
7.
8.
9.
10.